Ad Header



The Pulse of the Pharmaceutical Industry

Three-drug HIV regimen wins EU panel approval

Written by: | | Dated: Friday, April 27th, 2018


Gilead’s three-drug HIV regimen wins European panel approval


(Reuters) – Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.

The Committee for Medicinal Products for Human Use (CHMP) backed the treatment, Biktarvy, a once-daily tablet that combines two previously approved drugs – emtricitabine, tenofovir alafenamide and a new integrase inhibitor bictegravir.

The CHMP opinion sets the stage for a likely approval by the European Commission.

The combination, which was approved by the U.S. Food and Drug Administration in February, faced criticism from rival ViiV Healthcare, a joint venture majority-owned by GlaxoSmithKline Plc with Pfizer Inc and Shionogi Ltd.

The joint venture filed a lawsuit soon after the U.S. regulator’s approval alleging that Gilead was infringing patents on ViiV’s dolutegravir, a component of the company’s triple-drug HIV treatment Triumeq.


Reporting By Justin George Varghese in Bengaluru; Editing by Bernard Orr


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom